Standout Papers

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist 2023 2026 202490
  1. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist (2023)
    David P. Nichols, Sarah J. Morgan et al. Journal of Clinical Investigation

Immediate Impact

1 from Science/Nature 46 standout
Sub-graph 1 of 19

Citing Papers

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Combating Antibiotic-Resistant Bacterial Infection Using Coassembled Dimeric Antimicrobial Peptide-Based Nanofibers
2025 Standout
3 intermediate papers

Works of Sachinkumar B. Singh being referenced

Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients
2021
Sustained Coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in Cystic Fibrosis
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
Sachinkumar B. Singh 267 21 41 92 49 26 384
C. Shortt 289 20 45 96 25 13 342
Abaigeal Jackson 268 24 36 58 51 15 348
Rosaria Casciaro 271 34 48 53 25 27 340
Amanda Nymon 236 29 81 167 41 19 448
D. Mullane 319 44 76 63 19 22 429
Jonathan D. Cogen 351 24 125 52 29 46 426
Joseph Hatch 310 18 87 180 56 18 443
Christina S. Thornton 166 28 110 86 84 46 362
Daniela Dolce 203 9 44 165 51 29 353
Barbara Messore 318 25 58 39 16 16 381

All Works

Loading papers...

Rankless by CCL
2026